Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

March 26, 2014 4:55 PM

31 0

Conference Call with Insmed Management and Clinical Trial Investigators Will be Held Today at 8:00 a.m. Eastern Time

MONMOUTH JUNCTION, N.J. — Insmed Incorporated (Nasdaq GS:INSM) today reported results from the Company’s phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. The randomiz...

Read more

To category page

Loading...